BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below. This paper was submitted to a another journal from BMJ but declined for publication following peer review. The authors addressed the reviewers' comments and submitted the revised paper to BMJ Open. The paper was subsequently accepted for publication at BMJ Open.
Page 2 Line 6: how did the authors decide what instructions are complete? Looking at the table on page 5, some steps do not seem important to assess completeness eg taking off the dust cap which is logical. Other steps like priming the spray are not included, which would have much more of an impact on completeness. This point is applicable to lines 53-56 of the methods section.
Line 8-9: are the PILS from BNF and MHRA identical to what is provided in the spray pack to the patient? Also applicable to lines 50-52 of methods. If this is unknown then it should be added to the list of study limitations.
Page 3 Line 30. Word missing. Should read to minimise the risk of epistaxis Discussion. There should be some mention about nasal drops too and why they were excluded from the study.
Conclusión. Also worth mentioning that patients often have to change their nasal sprays due to price differences, stock availability etc. It is confusing when they discover the new sprays have a completely different set of instructions. One can presume that consistent instructions would encourage confidence in the treatment regimen .  Page 5  It would be beneficial to have another table showing each spray and a box with a tick or cross as to whether the instruction is supplied. This would be a better way to illustrate the wide variability. As we know spray advice varies wildly. In addition to presenting the data more clearly, this revised table will help guide clinicians to choosing which spray instructions fits with their agreed departmental policy and this may have an influence on which sprays they recommend to their patients.
VERSION 1 -AUTHOR RESPONSE
Page 2 Line 6: how did the authors decide what instructions are complete? Looking at the table on page 5, some steps do not seem important to assess completeness eg taking off the dust cap which is logical. Other steps like priming the spray are not included, which would have much more of an impact on completeness. This point is applicable to lines 53-56 of the methods section. Authors' response: In the analysis of the PILs of different INCS a distinction can be made in steps for priming, daily administration and cleaning of the INCS. In this analysis, we only distinguished the consecutive steps for daily administration of INCS and we disregarded the steps for priming and cleaning. We categorised all steps for daily administration that were mentioned in the PILs. Steps for priming of the INCS are not mentioned in the instructions for daily administration and taking of the dust cap is mentioned in most instructions. These instructions are separately mentioned in PILs in which also several steps can be distinguished. We think for this manuscript we should only exemplify the steps for daily administration of INCS and we think we should only mention the fact that we disregard the steps for priming and cleaning of the INCS: Methods, page 2, line 57-59: 'Steps for priming and cleaning of the sprays are also mentioned in PILs of INCS, which can also be distinguished in consecutive steps. In this analysis, we only exemplify all steps for daily administration of INCS as mentioned in the PILs.' Page 2 Line 8-9: are the PILS from BNF and MHRA identical to what is provided in the spray pack to the patient? Also applicable to lines 50-52 of methods. If this is unknown then it should be added to the list of study limitations. Authors' response: The MHRA and BNF website collect PILs of all products for market authorisation and are identical to what is provided in the spray pack to the patient. We added a statement about this in the manuscript. Methods, page 2, line 53: 'These PILs are identical to what is provided to the patient in the medicine pack.' Page 3 Line 30. Word missing. Should read to minimise the risk of epistaxis Authors' response: we added the missing word 'epistaxis': Discussion, page 3, line 33: 'To minimise the risk of epistaxis, a known AE of INCS, it is recommended to point the nozzle of the spray outward, away from the nasal septum [8] .' Discussion. There should be some mention about nasal drops too and why they were excluded from the study. Authors' response: we agree that there should be some mention about nasal drops and why they were excluded from the study, we added this mention to the discussion: Discussion, page 3, line 40-42: 'Furthermore, intranasal corticosteroids are also available in nasal drops. The instructions for administration of these intranasal corticosteroid drops differ from the instructions for administration of INCS and are therefore not included in this study.'
Conclusion. Also worth mentioning that patients often have to change their nasal sprays due to price differences, stock availability etc. It is confusing when they discover the new sprays have a completely different set of instructions. One can presume that consistent instructions would encourage confidence in the treatment regimen. Authors' response: we fully agree and we mentioned this in the manuscript. Conclusion, page 3, line 45-46: 'Patients sometimes have to change their INCS due to price differences, stock availability and sometimes efficacy. It is confusing that INCS have a completely other set of instruction.' Page 5 It would be beneficial to have another table showing each spray and a box with a tick or cross as to whether the instruction is supplied. This would be a better way to illustrate the wide variability. As we know spray advice varies wildly. In addition to presenting the data more clearly, this revised table will help guide clinicians to choosing which spray instructions fits with their agreed departmental policy and this may have an influence on which sprays they recommend to their patients. Authors' response: we agree and added Table 2 accordingly and see page below. Tables, page 6: ' Table 2 : Listed are the included INCS. Indicated is the working compound and dosage, the brand name if present, the manufacturer and the number of marketing authorisation holders if present. Also, illustrated is an overview of the consecutive steps for use of INCS as described in Table 1 . For each spray is indicated whether a specific step is supplied in the PIL, if supplied than the box is ticked with .' Results page 3, line 6-7: Table 1 shows how many PILs include instructions for each step and Table 2 shows an overview of each spray and whether the instruction is supplied. 
GENERAL COMMENTS
Many thanks to the authors for addressing concerns. I am happy to accept the article without any need for further revisions. Congratulations to the authors for a simple but well-conceived and relevant piece of work.
